Bioprocess, Journal Year: 2023, Volume and Issue: 13(04), P. 174 - 186
Published: Jan. 1, 2023
Language: Английский
Arthritis Research & Therapy, Journal Year: 2023, Volume and Issue: 25(1)
Published: Oct. 2, 2023
Abstract Background N6-methyladenosine (m6A) methylation modification is involved in the regulation of various biological processes, including inflammation, antitumor, and antiviral immunity. However, role m6A pathogenesis autoimmune diseases has been rarely reported. Methods Based on a description corresponding research methods, this review systematically summarizes current insights into mechanism diseases, especially its contribution to rheumatoid arthritis (RA) systemic lupus erythematosus (SLE). Results By regulating different provides promising biomarker for diagnosis treatment such diseases. Notably, variety immune cells mitochondrial energy metabolism. In addition, plays pathological processes RA, methylation-related genes can be used as potential targets RA therapy. Conclusions M6A an important SLE represents new target clinical treatment, providing ideas by targeting modification-related pathways.
Language: Английский
Citations
15
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(4), P. 4225 - 4225
Published: Feb. 20, 2023
RNA methylations play critical roles in processes, including splicing, nuclear export, nonsense-mediated decay, and translation. Regulators of have been shown to be differentially expressed between tumor tissues/cancer cells adjacent tissues/normal cells. N6-methyladenosine (m6A) is the most prevalent internal modification RNAs eukaryotes. m6A regulators include writers, demethylases, binding proteins. Since important regulating expression oncogenes suppressor genes, targeting can a strategy for developing anticancer drugs. Anticancer drugs are clinical trials. regulator-targeting could enhance effects current chemotherapy This review summarizes cancer initiation progression, autophagy, drug resistance. The also discusses relationship autophagy resistance, effect high levels on potential values as diagnostic markers therapeutic targets.
Language: Английский
Citations
11
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Nov. 13, 2024
Autoimmune diseases comprise a large group of conditions characterized by complex pathogenesis and significant heterogeneity in their clinical manifestations. Advances sequencing technology have revealed that addition to genetic susceptibility, various epigenetic mechanisms including DNA methylation histone modification play critical roles disease development. The emerging field epigenetics has provided new perspectives on the development autoimmune diseases. Aberrant modifications can be used as biomarkers for diagnosis prognosis. Exploration human profiles patients with exhibit markedly altered compared healthy individuals. Targeted cutting-edge therapies are emerging. For example, inhibitors rectify dysregulation relieve patients. Histone deacetylase such vorinostat affect chromatin accessibility further regulate gene expression, been treating hematological malignancies. Epigenetic opened avenues precise treatment offer opportunities improved therapeutic outcomes. Our review aid comprehensively elucidation targeted ultimately benefit these conditions.
Language: Английский
Citations
4
Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 157 - 157
Published: Jan. 21, 2025
N6-methyladenosine (m6A) is the most abundant, dynamically reversible, and evolutionarily conserved internal chemical modification in eukaryotic RNA. It emerging as critical for regulating gene expression at post-transcriptional level by affecting RNA metabolism through, example, pre-mRNA processing, mRNA decay, translation. ALKBH5 has recently been identified an endogenous m6A demethylase implicated a multitude of biological processes. This review provides overview structural functional characteristics involvement diverse human diseases, including metabolic, immune, reproductive, nervous system disorders, well development inhibitors. In summation, this highlights current understanding structure, functions, detailed mechanisms various physiological pathological processes valuable insights clinical applications foundational research within related fields.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 24, 2025
Dynamic changes in various forms of RNA modification are critical to the functional homeostasis immune system and pathophysiology autoimmune diseases. modification-related proteins play an essential role these processes. At present, research methods diseases mainly detect expression tissues or cells, but there is a lack explorations target RNAs in-depth mechanisms. Considering important CD4 + T cell dysfunction pathogenesis progression diseases, regulatory effect abnormal on cells deserves attention, which will provide perspective for further exploring mechanism In this Review, we discuss patients with highlight effects cells.
Language: Английский
Citations
0
Clinical Reviews in Allergy & Immunology, Journal Year: 2024, Volume and Issue: 66(3), P. 401 - 422
Published: Aug. 29, 2024
Language: Английский
Citations
2
Immunity Inflammation and Disease, Journal Year: 2024, Volume and Issue: 12(8)
Published: Aug. 1, 2024
Abstract Background N6‐methyladenosine (m6A) has been identified as the most abundant modification of RNA molecules and aberrant m6A modifications have associated with development autoimmune diseases. However, role in ankylosing spondylitis (AS) not adequately investigated. Therefore, we aimed to explore significance regulator‐mediated methylation AS. Methods The methylated immunoprecipitation sequencing (meRIP‐seq) digital (Digital RNA‐seq) were conducted using peripheral blood mononuclear cells from three AS cases healthy controls, identify genes affected by abnormal methylation. different peaks cross‐referenced AS‐related obtained GeneCards Suite. Subsequently, expression levels shared differentially expressed (DEGs) key regulators evaluated data 68 36 controls two sets (GSE25101 GSE73754). In addition, results validated through quantitative polymerase chain reaction (qPCR). Results meRIP‐seq Digital RNA‐seq analyses 28 upregulated but downregulated expression, 52 expression. By intersecting 2184 Suite, a total five DEGs: BCL11B , KAT6B IL1R1 TRIB1 ALDH2 . Through analysis qPCR, found that Moreover, regulators, WTAP heterogeneous nuclear ribonucleoprotein C, identified. Conclusions conclusion, current study revealed plays crucial might hence provide new treatment strategy for disease.
Language: Английский
Citations
1
Biomolecules, Journal Year: 2024, Volume and Issue: 14(8), P. 1042 - 1042
Published: Aug. 22, 2024
N6-methyladenosine (m6A) represents the most prevalent and significant internal modification in mRNA, with its critical role gene expression regulation cell fate determination increasingly recognized recent research. The immune system, essential for defense against infections maintaining stability through interactions other bodily systems, is significantly influenced by m6A modification. This acts as a key post-transcriptional regulator of responses, though effects on different cells vary across diseases. review delineates impact major system-related cancers—including those respiratory, digestive, endocrine, nervous, urinary reproductive, musculoskeletal system malignancies, well acute myeloid leukemia autoimmune We explore pathogenic roles RNA modifications within tumor microenvironment broader highlighting how regulators interact pathways during disease progression. Furthermore, we discuss patterns these can influence susceptibility to immunotherapy, facilitating development diagnostic prognostic models pioneering new therapeutic approaches. Overall, this emphasizes challenges prospective directions m6A-related various systemic diseases throughout body.
Language: Английский
Citations
1
Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(9), P. 967 - 967
Published: Sept. 12, 2024
Sjögren's syndrome (SS) is an autoimmune disease characterized by heterogeneous clinical presentation and the presence of various autoantibodies. This study aimed to determine differences in findings according antibody positivity patients with primary Sjögren (pSS) Turkish population. A retrospective was conducted 402 (378 women 24 men) pSS were analyzed. The categorized into three subgroups based on serological tests. These (1) quadruple seropositivity (positive for anti-Sjögren's syndrome-related antigen antibodies (anti-SSA; anti-Ro) B (anti-SSB; anti-La), rheumatoid factor (RF), antinuclear (ANA); (2) double ANA anti-SSA/Ro antibodies); (3) seronegativity (negative ANA, RF, anti-SSB/La antibodies). number quadruple-seropositive 72 (18.6%), double-seropositive 174 (43.2%), quadruple-seronegative 85 (21.1%). age at diagnosis 42.4 ± 10.8, which significantly younger than that (
Language: Английский
Citations
0
Bioprocess, Journal Year: 2023, Volume and Issue: 13(04), P. 174 - 186
Published: Jan. 1, 2023
Language: Английский
Citations
0